Markets

Merck KGaA Announces Orphan Drug Designation For Tepotinib In Japan

(RTTNews) - Merck KGaA said that the Japanese Ministry of Health, Labour and Welfare has granted orphan drug designation for its investigational therapy tepotinib for patients with non-small cell lung cancer or NSCLC harboring MET gene alterations.

The Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists.

Tepotinib is also being investigated in the INSIGHT 2 study (NCT03940703) in combination with the tyrosine kinase inhibitor (TKI) osimertinib in epidermal growth factor receptor (EGFR) mutated, MET amplified, locally advanced or metastatic NSCLC having acquired resistance to prior EGFR TKI.

In March 2018, tepotinib received SAKIGAKE 'fast-track' regulatory designation in Japan and in September 2019 received Breakthrough Therapy Designation in the U.S.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More